Introduction to Ameluz Photodynamic Therapy
Recent Phase 3 clinical trial findings have illuminated the potential of Ameluz photodynamic therapy as an effective treatment for actinic keratosis (AK) affecting the neck, trunk, and extremities. The therapy not only met its primary endpoint but also demonstrated a statistically significant advantage over vehicle gel, reinforcing its clinical efficacy across various body sites.
Study Overview
The multicenter, randomized, double-blind, vehicle-controlled Phase 3 study focused on the efficacy and tolerability of field-directed Ameluz® PDT compared to vehicle PDT in patients with AKs. A total of 172 patients participated, with a random allocation of 4:1 to receive either Ameluz® gel or the vehicle gel.
Treatment Administration
Patients received treatment involving one to three tubes of Ameluz® applied to areas measuring approximately 80, 160, or 240 cm². This was followed by photodynamic therapy using a RhodoLED® XL or BF-RhodoLED® lamp. If AK lesions persisted, a second treatment was administered at Week 12. The study design included a follow-up period of about one year post-final treatment.
Primary Endpoint Achievement
The primary endpoint was defined as the “subject complete clearance rate,” which measured the percentage of patients who achieved full clearance of all treated AK lesions 12 weeks after the last PDT session. The results were compelling: Ameluz® PDT achieved a complete clearance rate of 45.6% in the Full Analysis Set (FAS), significantly higher than the 16.7% observed in the vehicle group (p < 0.0003). In the Per Protocol Set (PPS), the rates were 53.2% for Ameluz® PDT versus 22.2% for the vehicle.
Secondary Outcomes
In addition to the primary endpoint, secondary outcomes underscored the efficacy of Ameluz® PDT. The clearance of AK lesions 12 weeks after the last treatment was 73.1% in the FAS and 80.3% in the PPS. Notably, the clearance rates varied by anatomical location, with rates of 38.5% and 46.5% in the extremities and 74.1% and 78.3% on the neck and trunk, respectively.
Patient Satisfaction and Cosmetic Outcomes
Beyond efficacy, the study also highlighted the favorable cosmetic outcomes associated with Ameluz® PDT. Investigators noted that 75.2% of patients rated the aesthetic appearance of their treated skin as “good” or “very good.” Meanwhile, patient satisfaction was high, with 70.9% of participants expressing similar positive assessments. Remarkably, 86.3% stated they would opt for PDT again for future treatments.
Implications for Broader Treatment
Hermann Luebbert, CEO and Chairman of Biofrontera Inc., emphasized the significance of these results, marking a pivotal moment in their clinical program. He noted that the data supports Ameluz®’s potential to address larger, high-burden AK fields beyond just the face and scalp. Such an expansion could significantly widen its clinical applications, benefiting patients with actinic keratoses in various sun-exposed areas.
Expanding Treatment Options
Nathalie Zeitouni, a prominent dermatologist involved in the study, echoed the sentiment that Ameluz® PDT already serves as a valuable treatment for AK on the face and scalp. The trial results bolster the argument for expanding treatment options for physicians and their patients, especially those presenting lesions in other body areas.
Future Directions
Encouraged by these promising Phase 3 results, Biofrontera plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration in the third quarter of 2026. This step could lead to a significant advancement in the treatment of actinic keratosis, providing new hope for patients affected by this condition.
Conclusion
The findings from the Phase 3 trial of Ameluz photodynamic therapy signify a promising stride in the management of actinic keratosis. With its demonstrated efficacy and favorable patient outcomes, Ameluz® could redefine treatment practices and expand therapeutic options for individuals dealing with AK across various body areas. The future of photodynamic therapy looks bright, with the potential to enhance patient quality of life significantly.
Key Takeaways
- Ameluz photodynamic therapy shows significant efficacy for actinic keratosis on various body sites.
-
The therapy achieved a complete clearance rate of 45.6% in the trial, outperforming vehicle gel significantly.
-
High patient satisfaction rates suggest favorable cosmetic outcomes and a willingness to choose PDT again.
-
Biofrontera plans to submit an sNDA to the FDA, marking a potential expansion in the treatment landscape for AK.
-
The results underscore the therapy’s potential to address larger AK fields beyond the face and scalp.
Read more → medicaldialogues.in